Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis

Abstract

Despite remarkable efficacy, there is an emerging concern regarding TKI-associated cardiovascular toxicity in CML. Long term follow-up studies on association between TKI therapy and cardiovascular outcome have been limited. CML patients were accessed from the SEER 18 database from 1992 to 2011. Cardiovascular disease (CVD) specific mortality was calculated comparing the pre-TKI era to the TKI era using the Fine-Gray competing risk model. Overall, the TKI era was associated with a reduced cardiovascular mortality compared with the pre-TKI era (HR = 0.72; 95%CI, 0.59–0.89). Our results argue for continued aggressive screening, identification and management of cardiovascular risk factors among all CML patients, especially the elderly, and further investigation into specific mechanisms, factors and predictors of risks in TKI-treated CML.

Keywords:

• Chronic myeloid leukemia
• tyrosine kinase inhibitor
• cardiovascular mortality
• imatinib
• SEER

Disclosure statement

Disclosure for Dr. Michael J. Mauro: Takeda: Consultancy; Pfizer: Consultancy; Novartis: Consultancy, Research Funding (Institutional); Bristol-Myers Squibb: Consultancy, Research Funding (Institutional); Sun/SPARC: Research Funding (Institutional).

The rest of the authors have no conflicts of interest to disclose.